[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335820-105":59,"doc-detail-335820-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","long-term-breast-cancer-response-to-cdk46-inhibition-defined-by-tp53-mediated-geroconversion","Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion","","In metastatic HR+ breast cancer, only a subset of patients maintain long-term disease control under CDK4/6 inhibition. A clinically annotated patient cohort shows TP53 loss (27.6%) and MDM2 amplification (6.4%) correlate with failure of prolonged control. Breast cancer models indicate p53 loss preserves CDK4/6 activity but promotes drug-insensitive p130 phosphorylation via CDK2, preventing DREAM complex assembly, driving cell-cycle re-entry and progression. CDK2 inhibitors can induce geroconversion and senescence phenotypes, with combined CDK4/6 and CDK2 blockade needed across diverse tumors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/long-term-breast-cancer-response-to-cdk46-inhibition-defined-by-tp53-mediated-geroconversion/335820/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/long-term-breast-cancer-response-to-cdk46-inhibition-defined-by-tp53-mediated-geroconversion/335820.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which genetic alterations are linked to lack of long-term disease control under CDK4/6 inhibition?","Question",{"text":112,"@type":113},"TP53 loss (27.6%) and MDM2 amplification (6.4%) are associated with failure of long-term disease control in metastatic HR+ breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does p53 loss affect CDK4/6 inhibitor response mechanistically?",{"text":117,"@type":113},"p53 loss does not change CDK4/6 activity or G1 blockade; instead it promotes drug-insensitive p130 phosphorylation by CDK2, which prevents DREAM complex assembly and enables cell-cycle re-entry.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic strategy can overcome TP53 loss in HR+ breast cancer models?",{"text":121,"@type":113},"Inhibitors of CDK2 can overcome p53 loss by inducing geroconversion and senescence phenotypes, and complete long-term response appears to require combined CDK4/6 and CDK2 kinase inhibition.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335820,1790148894,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":24,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Author Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Cancer Cell. Author manuscript; available in PMC 2025 December 12. |\n| --- | --- |\n\nPublished in final edited form as:  \nCancer Cell. 2024 November 11; 42(11): 1919–1935.e9. doi:10.1016/j.ccell.2024.09.009 .  \nLong-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion  \nRei Kudo 1,8,17 , Anton Safonov2,16,17 , Catherine Jones 1 , Enrico Moiso3,4 , Jonathan R. Dry5 , Hong Shao 1 , Sharanya Nag 1 , Edaise M. da Silva6 , Selma Yeni Yildirim6 , Qing Li 1 , Elizabeth O’Connell 1 , Payal Patel 1 , Marie Will 1,2,7 , Atsushi Fushimi8 , Marimar Benitez 14 , Martina Bradic 14 , Li Fan9 , Harikrishna Nakshatri 10 , Dhivya R. Sudhan 11 , Christopher R. Denz 11 , Iker Huerga Sanchez5 , Jorge S. Reis-Filho6 , Shom Goel 12,13 , Andrew Koff14 , Britta Weigelt6 , Qamar J. Khan 15 , Pedram Razavi2,16,* , Sarat Chandarlapaty 1,2,16,18,*  \n1 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSK), New York, NY 10065, USA  \n2Breast Medicine Service, Department of Medicine, MSK, New York, NY 10065, USA  \n3 Department of Medicine, MSK, New York, NY 10065, USA  \n4 Department of Epidemiology and Biostatistics, MSK, New York, NY 10065, USA  \n5Tempus AI, Boston, MA 02110, USA  \n6 Department of Pathology and Laboratory Medicine, MSK, New York, NY 10065, USA  \n7Clinical Genetics Service, Department of Medicine, MSK, New York, NY 10065, USA  \n8 Department of Surgery, The Jikei University School of Medicine, Tokyo 1058461, Japan  \n9 Helen and Robert Appel Alzheimer’s Disease Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA  \n10 Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA  \n11Oncology R&D, AstraZeneca, Waltham, MA 02451, USA  \n12 Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia  \n13The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3000, Australia  \n14 Program in Molecular Biology, Sloan Kettering Institute, MSK, New York, NY 10065, USA  \nThis is an open access article under the CC BY-NC license ([http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)).  \n*Correspondence: [razavip@mskcc.org](razavip@mskcc.org) (P.R.), [chandars@mskcc.org](chandars@mskcc.org) (S.C.) .  \nAUTHOR CONTRIBUTIONS  \nS.C., P.R., R.K., and A.S. conceptualized and designed the study. R.K., Q.L., H.S., E.M.d.S., E.O., S.N., S.Y.Y., P.P., M.B., and  \nC.J. performed the experiments. R.K., H.S., J.S.R.-F., S.G., P.R., E.M.d.S., S.N., P.P., Q.L., D.R.S., and C.D. analyzed experimental data. A.F., E.M., M.B., and L.F. performed the computational analyses of the RNA sequencing data. Q.J.K. performed clinical trial and provided samples. H.N. established PDX models. D.R.S and C.D. provided the information of drug. B.W., J.S.R.-F., S.Y.Y., and E.M.d.S. performed tissue procurement, biological substrates, and data generation. D.R.D., P.R., J.R.D., and A.S. performed the bioinformatics and genomic analyses. I.H.S. conducted the validation analyses. S.C., J.S.R.-F., A.K., S.G., P.R., B.W., and M.W. supervised the experiments. A.K., P.R., Q.L., and M.W. reviewed and edited the writing. The manuscript was written by S.C., R.K., P.R., A.S., E. M., E.M.d.S., H.S., and A.F. with assistance from all authors. All authors read and approved of the paper.  \nAuthor Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \nKudo et al. Page 2  \n15 Division of Medical Oncology, The University of Kansas Medical Center, Kansas City, KS 66160, USA  \n16Weill Cornell Medical College, New York, NY 10065, USA  \n17These authors contributed equally  \n18Lead contact  \nSUMMARY  \nInhibition ofCDK4/6 kinases has led to improved outcomes in breast cancer. Nevertheless, only a minority of patients experience long-term disease con","cbCaiiNsmjPExiHw","https://ap.wps.com/l/cbCaiiNsmjPExiHw","pdf",2627550,45,"English","# Summary\n# In brief\n# Introduction","[{\"question\":\"Which genetic alterations are linked to lack of long-term disease control under CDK4/6 inhibition?\",\"answer\":\"TP53 loss (27.6%) and MDM2 amplification (6.4%) are associated with failure of long-term disease control in metastatic HR+ breast cancer.\"},{\"question\":\"How does p53 loss affect CDK4/6 inhibitor response mechanistically?\",\"answer\":\"p53 loss does not change CDK4/6 activity or G1 blockade; instead it promotes drug-insensitive p130 phosphorylation by CDK2, which prevents DREAM complex assembly and enables cell-cycle re-entry.\"},{\"question\":\"What therapeutic strategy can overcome TP53 loss in HR+ breast cancer models?\",\"answer\":\"Inhibitors of CDK2 can overcome p53 loss by inducing geroconversion and senescence phenotypes, and complete long-term response appears to require combined CDK4/6 and CDK2 kinase inhibition.\"}]","Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion | PDF",1790012417,113,[147,151,155,159,163],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/05489e9b2da1052c870c8bf9d7de6bd6.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/45be3300ba73c2250bb0bf3f1099f484.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/260ca253db86bbdf55f84edf18e2fea7.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/433ea0d6f531ed46a1a93004708b272a.webp",980,1268,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/6d4bcc622d9d8185d4687ab0cbffe987.webp",979,1267]